

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, April 27, 2022 for the purposes of, among other matters, considering and approving the unaudited first quarterly results of the Company and its subsidiaries for the first quarter ended March 31, 2022 and its publication.

By order of the Board

RemeGen Co., Ltd.*

Mr. Wang Weidong

Chairman and executive director

Yantai, The PRC

April 13, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

* For identification purposes only